Claims:

1. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating epilepsy, tonic clonic seizures and/or absence seizures, wherein the pharmaceutical composition is to be administered with a pharmaceutical composition comprising a second active ingredient selected from the group consisting of(S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the second active ingredient is (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide or a pharmaceutically acceptable salt thereof.

3. The use according to claim 1, wherein the second active ingredient is 2-propylpentanoic acid or a pharmaceutically acceptable salt thereof.

4. The use according to any one of claims 1 to 3, wherein the N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the second active ingredient are comprised in a single pharmaceutical composition.

5. The use according to any one of claims 1 to 3, wherein the N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the second active ingredient are comprised in separated pharmaceutical compositions.

6. The use according to any one of claims 1 to 5, in the manufacture of a medicament for treating epilepsy.

7. The use according to any one of claims 1 to 5 in the manufacture of a medicament for treating tonic clonic and/or absence seizures.

8. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically

acceptable salt thereof, and at least one therapeutically inert excipient, in the manufacture of a medicament for treating epilepsy, wherein the pharmaceutical composition is to be administered in combination with a second pharmaceutical composition containing, an active ingredient, (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

9. A kit of parts comprising a first pharmaceutical composition comprising, as an active ingredient, N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient; and a second pharmaceutical composition comprising an active ingredient selected from the group consisting of (*S*)-2-(2-oxopyrrolidin-1-yl)butanamide and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

10. Use of a pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating epilepsy, wherein the pharmaceutical composition is to be administered with a pharmaceutical composition comprising an active ingredient selected from the group consisting (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, wherein at least one of the N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, administered to the subject is to be administered at an inactive or a partially active dosage compared to the dosage when the active ingredient is administered alone.

11. The use of claim 10, wherein the pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition comprising an active ingredient selected from the group consisting of (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, is to be administered sequentially.

12. The use of claim 10, wherein the pharmaceutical composition comprising N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-

acetamide, or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition comprising an active ingredient selected from the group consisting of (S)-2-(2-oxopyrrolidin-1-yl)butanamide, and 2-propylpentanoic acid, or a pharmaceutically acceptable salt thereof, is to be administered simultaneously.